Published in Hematol Oncol on July 05, 1990
Malignant MCF10CA1 cell lines derived from premalignant human breast epithelial MCF10AT cells. Breast Cancer Res Treat (2001) 3.77
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res (1997) 2.96
Durable treatment-free remission after high-dose cyclophosphamide therapy for previously untreated severe aplastic anemia. Ann Intern Med (2001) 2.47
Venoocclusive disease of the liver following bone marrow transplantation. Transplantation (1987) 2.35
Antimitotic natural products combretastatin A-4 and combretastatin A-2: studies on the mechanism of their inhibition of the binding of colchicine to tubulin. Biochemistry (1989) 2.34
Phase I study of bryostatin 1: assessment of interleukin 6 and tumor necrosis factor alpha induction in vivo. The Cancer Research Campaign Phase I Committee. J Natl Cancer Inst (1993) 2.22
Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data. J Biol Chem (1991) 1.97
Inhibition of cyclin-dependent kinases, GSK-3beta and CK1 by hymenialdisine, a marine sponge constituent. Chem Biol (2000) 1.71
Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod (1987) 1.64
Two phases of engraftment established by serial bone marrow transplantation in mice. Blood (1989) 1.58
Bryostatin 1 down-regulates mdr1 and potentiates vincristine cytotoxicity in diffuse large cell lymphoma xenografts. Clin Cancer Res (1998) 1.57
Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J Biol Chem (1994) 1.55
Interactions of tubulin with potent natural and synthetic analogs of the antimitotic agent combretastatin: a structure-activity study. Mol Pharmacol (1988) 1.54
Phosphorylation of lamin B at the nuclear membrane by activated protein kinase C. J Biol Chem (1988) 1.52
Zinc finger domains and phorbol ester pharmacophore. Analysis of binding to mutated form of protein kinase C zeta and the vav and c-raf proto-oncogene products. J Biol Chem (1994) 1.49
Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C. Proc Natl Acad Sci U S A (1988) 1.49
Bryostatin 1 (bryo1)-induced monocytic differentiation in THP-1 human leukemia cells is associated with enhanced c-fyn tyrosine kinase and M-CSF receptors. Leuk Res (1997) 1.48
In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer (1999) 1.47
Binding of dolastatin 10 to tubulin at a distinct site for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites. J Biol Chem (1990) 1.47
Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis (1987) 1.44
Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. J Nat Prod (1992) 1.43
Genetic markers in thyroid tumors. Surgery (1991) 1.39
Dolastatin 10, a powerful cytostatic peptide derived from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid binding domain. Biochem Pharmacol (1990) 1.34
Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res (1999) 1.31
The spongistatins, potently cytotoxic inhibitors of tubulin polymerization, bind in a distinct region of the vinca domain. Biochemistry (1995) 1.29
Differential effects of bryostatins and phorbol esters on arachidonic acid metabolite release and epidermal growth factor binding in C3H 10T1/2 cells. Cancer Res (1988) 1.28
Spongistatin 1, a highly cytotoxic, sponge-derived, marine natural product that inhibits mitosis, microtubule assembly, and the binding of vinblastine to tubulin. Mol Pharmacol (1993) 1.28
Antineoplastic agents, 256. Cell growth inhibitory isocarbostyrils from Hymenocallis. J Nat Prod (1993) 1.26
The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1. Proc Natl Acad Sci U S A (1998) 1.25
The guanine nucleotide exchange factor RasGRP is a high -affinity target for diacylglycerol and phorbol esters. Mol Pharmacol (2000) 1.24
Magnetic resonance imaging to measure therapeutic response using an orthotopic model of human pancreatic cancer. Pancreas (2000) 1.20
Ubiquitination of protein kinase C-alpha and degradation by the proteasome. J Biol Chem (1996) 1.19
The interaction with tubulin of a series of stilbenes based on combretastatin A-4. Br J Cancer (1995) 1.19
Anticonvulsant-induced aplastic anemia: increased susceptibility to toxic drug metabolites in vitro. Blood (1983) 1.17
Complete remission in severe aplastic anemia after high-dose cyclophosphamide without bone marrow transplantation. Blood (1996) 1.16
A unique EBV-negative low-grade lymphoma line (WSU-FSCCL) exhibiting both t(14;18) and t(8;11). Cancer Genet Cytogenet (1993) 1.14
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines. Blood (1997) 1.13
Bryostatins: potent, new mitogens that mimic phorbol ester tumor promoters. Biochem Biophys Res Commun (1985) 1.13
Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents. Pancreas (1998) 1.11
Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood (1994) 1.11
Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer Suppl (1996) 1.10
Bryostatin 1 and phorbol ester down-modulate protein kinase C-alpha and -epsilon via the ubiquitin/proteasome pathway in human fibroblasts. Mol Pharmacol (1997) 1.09
Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A (1987) 1.08
Three activators of protein kinase C, bryostatins, dioleins, and phorbol esters, show differing specificities of action on GH4 pituitary cells. J Biol Chem (1986) 1.08
Antineoplastic components of marine animals. Nature (1970) 1.08
Potentiation of the activity of 1-beta-D-arabinofuranosylcytosine by the protein kinase C activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. Cancer Res (1992) 1.08
Bryostatin 1 activates protein kinase C and induces monocytic differentiation of HL-60 cells. Blood (1988) 1.07
Antineoplastic agents, 120. Pancratium littorale. J Nat Prod (1987) 1.07
Successful treatment of murine melanoma with bryostatin 1. Cancer Res (1991) 1.05
The role of protein kinase C isoenzymes in the growth inhibition caused by bryostatin 1 in human A549 lung and MCF-7 breast carcinoma cells. Int J Cancer (1994) 1.05
Bryostatin 1 protects protein kinase C-delta from down-regulation in mouse keratinocytes in parallel with its inhibition of phorbol ester-induced differentiation. Mol Pharmacol (1994) 1.04
Partial parallelism and partial blockade by bryostatin 1 of effects of phorbol ester tumor promoters on primary mouse epidermal cells. Cancer Res (1987) 1.04
Studies directed towards the refinement of the pancratistatin cytotoxic pharmacophore. Bioorg Med Chem Lett (2001) 1.04
Dolastatin 11, a marine depsipeptide, arrests cells at cytokinesis and induces hyperpolymerization of purified actin. Mol Pharmacol (2001) 1.03
A haploid expressed gene cluster exists as a single chromatin domain in human sperm. J Biol Chem (1995) 1.02
Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules. Biochem Pharmacol (1992) 1.01
Chromosomal markers of immortalization in human breast epithelium. Genes Chromosomes Cancer (1994) 1.01
Marrow transplanation in man following cyclophosphamide. Transplant Proc (1971) 1.01
Immune system reconstitution following allogeneic bone marrow transplantation in man: a multiparameter analysis. Transplant Proc (1976) 1.01
Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia. J Clin Oncol (1998) 1.00
Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro. Cancer Immunol Immunother (1994) 1.00
MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene (2010) 1.00
Inhibition of phorbol ester-induced T cell proliferation by bryostatin is associated with rapid degradation of protein kinase C. J Immunol (1993) 0.99
Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res (1989) 0.99
In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res (1993) 0.98
Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin Cancer Res (2000) 0.98
Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin. Biochem Pharmacol (1993) 0.98
Progenitor cell assays predict hematopoietic reconstitution after syngeneic transplantation in mice. Blood (1987) 0.98
A new anti-tubulin agent containing the benzo[b]thiophene ring system. Bioorg Med Chem Lett (1999) 0.98
Effects of the antimitotic natural product dolastatin 10, and related peptides, on the human malarial parasite Plasmodium falciparum. J Antimicrob Chemother (2003) 0.98
Structure-cytotoxic activity relationship for the toad poison bufadienolides. Bioorg Med Chem (1998) 0.98
The transient increase of tight junction permeability induced by bryostatin 1 correlates with rapid downregulation of protein kinase C-alpha. Exp Cell Res (2000) 0.98
Activation and growth of murine tumor-specific T-cells which have in vivo activity with bryostatin 1. Cancer Res (1992) 0.98
Synthesis and biological evaluation of aryl azide derivatives of combretastatin A-4 as molecular probes for tubulin. Bioorg Med Chem (2000) 0.97
Inhibition by bryostatin 1 of the phorbol ester-induced blockage of differentiation in hexamethylene bisacetamide-treated Friend erythroleukemia cells. Cancer Res (1987) 0.97
Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin. J Immunol (1990) 0.97
Antineoplastic agents 320: synthesis of a practical pancratistatin prodrug. Anticancer Drug Des (1995) 0.97
An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies. Clin Cancer Res (1998) 0.96
Binding of [26-3H]bryostatin 1 and analogs to calcium-dependent and calcium-independent protein kinase C isozymes. Mol Pharmacol (1994) 0.96
Demonstration of sub-nanomolar affinity of bryostatin 1 for the phorbol ester receptor in rat brain. Biochem Pharmacol (1988) 0.96
Dephosphorylation of activated protein kinase C contributes to downregulation by bryostatin. Am J Physiol (1996) 0.95
Phorbol ester-stimulated phosphorylation of PU.1: association with leukemic cell growth inhibition. Blood (1996) 0.95
The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Cancer Res (1996) 0.95
Characterization of the interaction of cryptophycin 1 with tubulin: binding in the Vinca domain, competitive inhibition of dolastatin 10 binding, and an unusual aggregation reaction. Cancer Res (1996) 0.95
p53 and protein kinase C independent induction of growth arrest and apoptosis by bryostatin 1 in a highly metastatic mammary epithelial cell line: In vitro versus in vivo activity. Int J Mol Med (1998) 0.94
Bryostatin 1 induces biphasic activation of protein kinase D in intact cells. J Biol Chem (1997) 0.94
Isolation and structure of five new cancer cell growth inhibitory bufadienolides from the Chinese traditional drug Ch'an Su. J Nat Prod (2001) 0.94
Phorbol ester and bryostatin differentially regulate the hydrolysis of phosphatidylethanolamine in Ha-ras- and raf-oncogene-transformed NIH 3T3 cells. Biochem J (1991) 0.94
Sustained intracellular retention of dolastatin 10 causes its potent antimitotic activity. Mol Pharmacol (2000) 0.93
Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res (2000) 0.93
Marinobufagenin impairs first trimester cytotrophoblast differentiation. Placenta (2006) 0.92
Antineoplastic agents, 118. Isolation and structure of bryostatin 9. J Nat Prod (1986) 0.92
A Semi-Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics. CPT Pharmacometrics Syst Pharmacol (2012) 0.92